Tumor News and Research

RSS

Combination therapy improves tumor response in HER2-positive breast cancer patients

A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Prostate cancer study identifies 295 genes associated with clinical recurrence following radical prostatectomy

Genomic Health, Inc. today announced the first results of a large prostate cancer study that identified 295 genes strongly associated with clinical recurrence following radical prostatectomy. Top-line findings from this study, which applied the same RT-PCR technology used in Genomic Health's Oncotype DX® breast and colon cancer tests, will be presented today at the Society for Urologic Oncology (SUO) annual meeting.

13 Dec 2010

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer, announced that today a poster highlighting positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer is being presented by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine at the AACR Breast Cancer Symposium in San Antonio, TX.

13 Dec 2010

CTCs in metastatic breast cancer patients linked to cancer recurrence, poor survival rates

Metastatic breast cancer patients who had circulating tumor cells (CTCs) in their blood before or after high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation had poor outcomes, according to researchers from the University of Texas MD Anderson Cancer Center.

13 Dec 2010

HOXB7 gene raises tamoxifen resistance in women with early-stage breast cancer

A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients' risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

High CTC level found to be early marker of poor outcome in metastatic breast cancer

A high level of circulating tumor cells (CTCs) - cells that have detached from a tumor and are circulating in the body through the blood - are an independent prognostic marker in metastatic breast cancer as first-line therapy.

13 Dec 2010

31-year-old mother with Gorham-Stout syndrome goes home with virtually rebuilt spine

Laurie Harms, Los Angeles, feared she'd never hold her infant daughter, Sky, again. A devastating and extremely rare bone-eroding disease - Gorham-Stout syndrome - had left the 31-year-old crumpled in a hospital bed - her neck broken, arms limp and useless, and voice muted by tubes.

10 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has requested and been granted a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its RIGS® technology Biologic License Application (BLA). The pre-IND meeting request is another step in Neoprobe's efforts to develop and commercialize the RIGS technology designed to enhance the surgical treatment of patients with solid tumor cancers.

10 Dec 2010

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).

10 Dec 2010

Blocking growth of blood vessels with antibodies could improve treatment of cancerous tumors

A novel strategy of blocking the growth of blood vessels with antibodies should result in improved treatment of cancerous tumors.

10 Dec 2010

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients - those with estrogen receptor (ER)-positive/HER2-negative disease.

10 Dec 2010

Researchers target MIC-1 protein to halt growth of melanoma tumors

Halting the growth of melanoma tumors by targeting the MIC-1 protein that promotes blood vessel development in tumors may lead to better treatment of this invasive and deadly cancer, according to Penn State College of Medicine researchers in The Foreman Foundation Research Laboratory.

10 Dec 2010

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that a Phase 3 pivotal study with OncoVEXGM-CSF for the first line treatment of patients with locally advanced squamous cell carcinoma of the head & neck has commenced.

10 Dec 2010

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Memgen, LLC announced the presentation of clinical and preclinical results for its lead product, ISF35, during the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The research and clinical development of ISF35 announced today was led by Januario Castro, MD, and Thomas Kipps, MD, PhD, both at the University of California, San Diego.

10 Dec 2010

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies these high risk patients.

10 Dec 2010

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.

9 Dec 2010

Researchers discover central switch that regulates movement of cancer cells

Researchers at the University of Georgia have discovered a central switch that controls whether cells move or remain stationary. The misregulation of this switch may play a role in the increased movement of tumor cells and in the aggressiveness of tumors themselves.

9 Dec 2010

Enbrel outperforms Humira in treating newly diagnosed RA patients: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.

9 Dec 2010

Tumor News and Research

Combination therapy improves tumor response in HER2-positive breast cancer patients

Prostate cancer study identifies 295 genes associated with clinical recurrence following radical prostatectomy

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

CTCs in metastatic breast cancer patients linked to cancer recurrence, poor survival rates

HOXB7 gene raises tamoxifen resistance in women with early-stage breast cancer

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

High CTC level found to be early marker of poor outcome in metastatic breast cancer

31-year-old mother with Gorham-Stout syndrome goes home with virtually rebuilt spine

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Blocking growth of blood vessels with antibodies could improve treatment of cancerous tumors

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Researchers target MIC-1 protein to halt growth of melanoma tumors

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Researchers discover central switch that regulates movement of cancer cells

Enbrel outperforms Humira in treating newly diagnosed RA patients: Report

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News